General Hematology
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
9 Feb, 2021 | 01:41h | UTCThrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases
Commentary on Twitter
Excellent review of thrombosis and anticoagulation in #COVID19 by @connors_md and @RMKGandhi
Paradoxically, anticoagulation may be most beneficial in moderately ill patients with #COVID19, as the bleeding risk may be excessive in the critically ill https://t.co/75TiNs0iej pic.twitter.com/v0avzhFl3f
— John Ross (@JohnRossMD) February 6, 2021
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
3 Feb, 2021 | 01:07h | UTCASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – Blood
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis
25 Jan, 2021 | 01:15h | UTCLong-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)